International Clinical Trial: PD-1 Monoclonal Antibody Combined With Gemcitabine and Cisplatin Followed by Selective Radiotherapy for Unresectable Locally Recurrent NPC

Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07528183) titled 'PD-1 Monoclonal Antibody Combined With Gemcitabine and Cisplatin Followed by Selective Radiotherapy for Unresectable Locally Recurrent NPC' on April 7.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Sun Yat-sen University

Condition: Nasopharyngeal Cancinoma (NPC)

Intervention: Drug: PD-1 monoclonal antibody combined with gemcitabine and cisplatin followed by selective radiotherapy

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: April 10, 2026

Target...